Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Consulting agrmnt
Upcoming conference date
Acq. announced
Director departure
Appointed director
Employment agrmnt
Quarterly results
RespireRx Pharmaceuticals Inc. (CORX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/02/2023 8-K Quarterly results
08/21/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
08/09/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Patent Family: Dronabinol Formulations [DRNB] RespireRx IP Patent Summary DRONABINOL Title: Lipid Nanoparticle Compositions and Methods for Formulating Insoluble Drugs Inventors: Lippa Serial Number: PCT/US2023/015875 Priority Date: 22 Mar 2022 International Filing Date: 22 Mar 2023 ABSTRACT: The present invention provides compositions and methods for formulating insoluble drugs using lipid nanoparticles. Title: Controlled, Low Dose Cannabinoid Compositions And Methods For Treatment Of Cannabinoid-Sensitive Disorders Low Dose Cannabinoid Medicaments Inventors: CARLEY; LETENDRE PCT/US2011/061490 [FD: 18 Nov 2011] US-CON No. 17/471,102 US Patent – Not Yet Issued File Date: 26 Jan 2021 Priority Date: 18 Nov 2010 Expire Date: 18 Nov 2031 ABSTRACT: The present invention provides methods for tre...",
"IN WITNESS WHEREOF, the",
"IN WITNESS WHEREOF, the",
"MASTER INTERCOMPANY SERVICES AGREEMENT This Master Intercompany Services Agreement is entered into as of August 3, 2023, by and between RespireRX Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware , and ResolutionRx Ltd., an Australian company . Provider and Recipient may each individually be referred to as a “Party” and collectively referred to as the “Parties”. RECITALS A. As of the date of this Agreement, Provider and Recipient are affiliates and Provider performs certain support activities in the form of both general and administrative and research and development support in the execution of business operations of Recipient; B. To support their ongoing operations, Recipients desire to secure the provision of such services by Provider; C....",
"GABAkines."
05/24/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "STRICTLY CONFIDENTIAL",
"RespireRx Demand Promissory Note and Warrant Purchase Agreement Arnold Lippa Family Trust of 2007",
"RespireRx-Arnold Lippa Family Trust of 2007 Demand Promissory Note",
"RespireRx-Arnold Lippa Family Trust of 2007 Warrant",
"RespireRx Demand Promissory Note and Warrant Purchase Agreement Marc M. Radin PC",
"RespireRx-Marc M. Radin PC Demand Promissory Note",
"RespireRx-Marc M. Radin PC Warrant",
"GABAkines.",
"Private & Confidential This LOI summarizes the principal terms of the proposed equity financing by Cantheon Capital, LLC through a private placement for ResolutionRx Ltd , an Australian unlisted public company with the intent to list on the Australian Securities Exchange , NASDAQ Capital Market, or any market equal to or higher than the OTCQB marketplace within eighteen months of the anniversary date of the services agreement with iNGENu CRO Pty Ltd ) and ResolutionRx. At the date of this LOI, ResolutionRx is a wholly-owned subsidiary of RespireRx Pharmaceuticals Inc., a Delaware corporation . The Cantheon investment will be a United States private placement, exempt from registration under the securities laws, rules and regulations of the United States and the various states of the US whic..."
05/05/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Schedule 1 – Series A Preference Share Terms RESOLUTIONRX LTD CERTIFICATE OF DESIGNATION, OF SERIES A PREFERENCE SHARES Section 1. Designation . The designation of preference shares, is the Series A Preference Shares . Section 2. Certain Definitions . For purposes of these Series A Preference Share Terms , in addition to the other terms defined herein, the following terms shall have the following meanings: “ Adjusted Conversion Price ” has the meaning provided in Section 6 . “ Affiliate ” means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed pursuant to section 50AA of the Corporations Act. With respect to a Holder, any investment fu..."
04/17/2023 10-K Annual Report for the period ended December 31, 2022
04/06/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "Respirerx PHARMACEUTICALS INC. CERTIFICATE OF DESIGNATION, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES I 8% REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW RespireRx Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware , hereby certifies that the Board of Directors of the Corporation , pursuant to authority of the Board of Directors as required by Section 151 of the Delaware General Corporation Law, and in accordance with the provisions of its Certificate of Incorporation and Bylaws, each as amended and restated through the date hereof, has and hereby authorizes a series of the Corporation’ s previously authorized preferred stock, and hereby states the designation and number of shares, and fixes the ...",
"FORM OF SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT , dated as of April ___, 2023 by and between RESPIRERX PHARMACEUTICALS INC., a Delaware corporation, with headquarters located at 126 Valley Road, Suite C, Glen Rock, NJ 07452 , and ___________, a __________________ . [Investor Name] [Jurisdiction of formation and nature of entity] WHEREAS: A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act of 1933, as amended and Rule 506 promulgated by the United States Securities and Exchange Commission under the 1933 Act; B. Buyer desires to purchase from the Company, and the Company desires to issue and sell to the Buyer, upon the terms and conditions set ..."
03/31/2023 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/28/2023 8-K Quarterly results
03/01/2023 8-K Quarterly results
02/01/2023 8-K Quarterly results
01/23/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "IN WITNESS WHEREOF, the",
"GABAkines."
01/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Dronabinol"
11/17/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/17/2022 8-K Quarterly results
11/14/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
11/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "AMPAkines."
11/07/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "AMPAkines."
09/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/22/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/15/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
08/03/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "PAYMENT SETTLEMENT AGREEMENT AND RELEASE This Agreement is made this 1st day of August, 2022 by and between Faegre Drinker Biddle & Reath LLP and RespireRx Pharmaceutical, Inc. . FDBR and RespireRx are referred to herein individually as “Party” and together as “Parties.” WHEREAS the Parties agree that, immediately prior to the execution of this Agreement, RespireRx owes to FDBR trade payables for legal services rendered and FDBR out-of-pocket expenses totalling $2,608,914.48; WHEREAS the Parties have reached an agreement regarding adjustment of the amount owed and payment terms as well as mutual releases; NOW, THEREFORE, for good and valuable consideration, and intending to be legally bound by this Agreement, the Parties agree as follows: 1. Settlement Amount: RespireRx will pay by wire tr..."
06/16/2022 8-K Quarterly results
05/23/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/16/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/16/2022 8-K Quarterly results
04/15/2022 10-K Annual Report for the period ended December 31, 2021
04/04/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "FIRST AMENDMENT TO THE PROMISSORY NOTE ISSUED ON MARCH 31, 2021 THIS FIRST AMENDMENT to the Note is entered into on April 1, 2022, but made effective as of March 31, 2022, by and between RespireRx Pharmaceuticals Inc., a Delaware corporation , and EMA Financial, LLC, a Delaware limited liability company . BACKGROUND A. The Company and Holder are the parties to that certain securities purchase agreement dated March 31, 2021, pursuant to which the Company issued to Holder a promissory note on even date in the original principal amount of $112,500.00 ; and B. The Parties desire to amend the Note as set forth expressly below. NOW THEREFORE, in consideration of the execution and delivery of the Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby..."
03/31/2022 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/28/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "To SECURITIES PURCHASE AGREEMENT This Amendment No. 1 dated March 24, 2022 and effective as of February 17, 2022 to Securities Purchase Agreement is made by and among RespireRx Pharmaceuticals Inc., a Delaware corporation and FirstFire Global Opportunities Fund LLC, a Delaware limited liability company . WHEREAS, Company and Holder are parties to that certain Securities Purchase Agreement dated as of February 17, 2021; WHEREAS, the Parties wish to amend the governing law from the State of New York to the State of Delaware; NOW, THEREFORE, in consideration of the mutual covenants and promises contained in the Note and this Amendment, the Parties hereby agree as follows: 1. Amendments . Section 8. entitled Governing Law; Miscellaneous. of the SPA shall be amended by replacing the first two s...",
"To CONVERTIBLE PROMISSORY NOTE This Amendment No. 2 dated March 24, 2022 and effective as of February 17, 2022 to Convertible Promissory Note as amended by Amendment No. 1, is made by and among RespireRx Pharmaceuticals Inc., a Delaware corporation and FirstFire Global Opportunities Fund LLC, a Delaware limited liability company . WHEREAS, Company and Holder are parties to that certain Convertible Promissory Note, dated February 17, 2021 which was amended on November 23, 2021, effective on November 17, 2021; WHEREAS, the Parties acknowledge that $80,000.00 of the principal amount and none of the accrued interest was repaid by the Company on November 8, 2021, leaving $32,000.00 of remaining principal amount plus accrued interest in an amount equal to the full amount of interest that would b..."
03/23/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Dronabinol"
03/08/2022 253G2 Form 253G2 -
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy